PT2906219T - Orvepitant para o tratamento do prurido crónico - Google Patents

Orvepitant para o tratamento do prurido crónico

Info

Publication number
PT2906219T
PT2906219T PT137741898T PT13774189T PT2906219T PT 2906219 T PT2906219 T PT 2906219T PT 137741898 T PT137741898 T PT 137741898T PT 13774189 T PT13774189 T PT 13774189T PT 2906219 T PT2906219 T PT 2906219T
Authority
PT
Portugal
Prior art keywords
orvepitant
treatment
chronic pruritus
pruritus
chronic
Prior art date
Application number
PT137741898T
Other languages
English (en)
Inventor
Emiliangelo Ratti
Michael Trower
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of PT2906219T publication Critical patent/PT2906219T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PT137741898T 2012-10-11 2013-10-09 Orvepitant para o tratamento do prurido crónico PT2906219T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11

Publications (1)

Publication Number Publication Date
PT2906219T true PT2906219T (pt) 2019-11-04

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137741898T PT2906219T (pt) 2012-10-11 2013-10-09 Orvepitant para o tratamento do prurido crónico

Country Status (24)

Country Link
US (3) US9603849B2 (pt)
EP (2) EP3597192A1 (pt)
JP (2) JP6815728B2 (pt)
KR (1) KR102202481B1 (pt)
CN (1) CN104703603A (pt)
AU (1) AU2013328695B9 (pt)
BR (1) BR112015006051A2 (pt)
CA (1) CA2884454C (pt)
CY (1) CY1122313T1 (pt)
DK (1) DK2906219T3 (pt)
EA (1) EA201590364A1 (pt)
ES (1) ES2750662T3 (pt)
HK (1) HK1211486A1 (pt)
HR (1) HRP20191955T1 (pt)
HU (1) HUE046508T2 (pt)
IL (1) IL237636B (pt)
LT (1) LT2906219T (pt)
MX (1) MX362879B (pt)
PL (1) PL2906219T3 (pt)
PT (1) PT2906219T (pt)
RS (1) RS59470B1 (pt)
SG (1) SG11201501867UA (pt)
SI (1) SI2906219T1 (pt)
WO (1) WO2014057003A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2906219T1 (sl) * 2012-10-11 2019-12-31 Nerre Therapeutics Limited Orvepitant za zdravljenje kroničnega pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
EP3478283A4 (en) * 2016-06-29 2020-07-22 Menlo Therapeutics Inc. USE OF NEUROKININ-1 ANTAGONISTS FOR TREATING VARIOUS PRURIGINAL DISORDERS
CN110996908A (zh) 2017-08-11 2020-04-10 株式会社爱茉莉太平洋 包含(r)-n-[1-(3,5-二氟-4-甲磺酰氨基-苯基)-乙基]-3-(2-丙基-6-三氟甲基-吡啶-3-基)-丙烯酰胺的药物组合物
MX2022002646A (es) 2019-09-05 2022-04-26 Incyte Corp Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica.
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ グループ リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
AU2008333131B2 (en) * 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
US20120077803A1 (en) * 2009-02-24 2012-03-29 Novartis Ag Uses Of NK Receptor Antagonists
EP2683376B1 (en) * 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN104245702B (zh) 2012-02-22 2016-09-14 利奥制药有限公司 新型神经激肽1受体拮抗剂化合物
SI2906219T1 (sl) * 2012-10-11 2019-12-31 Nerre Therapeutics Limited Orvepitant za zdravljenje kroničnega pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
BR112015006051A2 (pt) 2017-07-04
KR20150064732A (ko) 2015-06-11
US20170143711A1 (en) 2017-05-25
EP3597192A1 (en) 2020-01-22
KR102202481B1 (ko) 2021-01-12
SI2906219T1 (sl) 2019-12-31
PL2906219T3 (pl) 2020-02-28
AU2013328695A9 (en) 2018-04-26
RS59470B1 (sr) 2019-11-29
US20150238486A1 (en) 2015-08-27
JP6815728B2 (ja) 2021-01-20
EP2906219A1 (en) 2015-08-19
MX2015004162A (es) 2015-07-06
CA2884454A1 (en) 2014-04-17
AU2013328695B9 (en) 2018-05-17
AU2013328695A1 (en) 2015-04-02
EA201590364A1 (ru) 2015-11-30
EP2906219B1 (en) 2019-08-07
MX362879B (es) 2019-02-21
HRP20191955T1 (hr) 2020-01-24
CA2884454C (en) 2021-07-27
US9603849B2 (en) 2017-03-28
HK1211486A1 (en) 2016-05-27
WO2014057003A1 (en) 2014-04-17
US20190216806A1 (en) 2019-07-18
SG11201501867UA (en) 2015-04-29
AU2013328695B2 (en) 2018-04-05
DK2906219T3 (da) 2019-10-28
CN104703603A (zh) 2015-06-10
JP2019131594A (ja) 2019-08-08
CY1122313T1 (el) 2021-01-27
JP6953468B2 (ja) 2021-10-27
IL237636B (en) 2019-01-31
LT2906219T (lt) 2019-10-25
JP2015533136A (ja) 2015-11-19
ES2750662T3 (es) 2020-03-26
IL237636A0 (en) 2015-04-30
HUE046508T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
HK1211475A1 (en) Combination therapy
HK1206009A1 (en) Amino-substituted imidazopyridazines
HK1205512A1 (en) Amino-substituted imidazopyridazines
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
HK1213544A1 (zh) 新型二環苯基-吡啶/吡嗪用於治療癌症
ZA201906339B (en) Methods for treating pruritus
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
EP2921510A4 (en) SURFACE TREATMENT COMPOSITION
GB201219873D0 (en) Diverticulitis treatment
PL2833884T3 (pl) Zastosowanie inhibitorów ccr3
EP2925752A4 (en) PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201217439D0 (en) Combination therapy
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
EP2892529A4 (en) USES OF (-) - PERHEXILINE
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
PL2841079T3 (pl) Nowe kompozycje do leczenia przewlekłych owrzodzeń
GB201320905D0 (en) Therapeutic compounds
IL236873A0 (en) therapeutic compounds
GB201209283D0 (en) Liquid treatment